A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN)

Exclusion Criteria

• •Prior use of any investigational antibody therapy or other agent within 6 months of study start;
• •Prior use of any anti-cancer vaccine;
• •Prior use of standard anti-lymphoma/leukemia therapy or radiation therapy within 4 weeks of enrollment;
• •Prior use of MabThera (rituximab) within 8 weeks of study entry;
• •Prior administration of radioimmunotherapy 3 months prior to study entry;
• •Central nervous system (CNS) lymphoma.